Postpartum Low-Dose Aspirin and Preeclampsia

Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexFemale
Age18+
SponsorColumbia University

About this trial

The purpose of this research study is to find out whether women with severe preeclampsia taking low-dose aspirin (LDA) for 3 weeks post-delivery will experience an improvement in endothelial function (measured as flow-mediated dilation - FMD) and severity of disease, as the effects of preeclampsia can persist postpartum. Women diagnosed with severe preeclampsia prior to delivery will be enrolled and randomized to receive either low-dose aspirin (81mg) or placebo to take daily for up to 3 weeks post-delivery. Exploratory objective includes healthy control postpartum patients without preeclampsia and not on LDA during pregnancy or postpartum in comparison with the primary study population affected by preeclampsia with severe features.

Eligibility criteria

Qualifiers

Singleton or Multiple gestation

Maternal age >= 18 years

20 0/7 weeks gestation or greater

Severe Preeclampsia diagnosed prior to delivery

Disqualifiers

Aspirin use postpartum for other medical indication

Lovenox, unfractionated heparin, or other anticoagulant use postpartum for an indication other than postoperative (in-house)

Aspirin use within 7 days of planned initial FMD testing postpartum

Hypersensitivity or allergy to Aspirin or other salicylates

Trial design

Treatments tested in this trial

  • Aspirin tablet
  • Placebo oral capsule

Treatment groups

100 Participants
are divided into 3 treatment groups

Sponsors and collaborators